Skip to main content

Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?

Abstract

Background

Recent papers consider surgery as an option for synchronous liver oligometastatic patients [metastatic pancreatic ductal adenocarcinoma (mPDAC)]. In this study, we present our series of resected mPDACs after neoadjuvant chemotherapy (nCT).

Patients and methods

All patients resected after downstaging of mPDAC were included in this study. Downstaging criteria were disappearance of liver metastasis and a decrease in cancer antigen (CA) 19-9. The type and duration of nCT, last nCT surgery interval, histology, morbidity, and mortality were recorded, and overall survival (OS) and disease-free survival (DFS) were analyzed.

Results

Overall, 24 of 535 patients (4.5%) observed with mPDAC were included. These patients received gemcitabine alone (5/24), gemcitabine + nanoparticle albumin-bound (nab)−paclitaxel (3/24), and FOLFIRINOX (16/24). Primary tumor size decreased from 31 to 19 mm (p < 0.001), and serum CA19-9 decreased from 596 to 18 U/mL (p < 0.001). In 14/24 patients, the tumor was located in the head. Median interval nCT surgery was 2 months, there were no mortalities, and the postoperative course was uneventful in 34% of cases. Grade B/C pancreatic fistula, postoperative bleeding, and sepsis occurred in 17/4, 4, and 12% of cases, respectively, and reoperation rate was 4%. R0 resection was achieved in 88% of cases, with 17% complete pathological response. Positive nodes were found in 9/24 patients with a median node ratio of 0.37, and OS and DFS was 56 and 27 months, respectively.

Conclusions

Patients with mPDAC who were fully responsive to nCT may be cautiously considered for surgery, with potential benefit in survival compared with palliative chemotherapy alone. This is supported by results of our retrospective study, which is the largest ever reported.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. 2.

    Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016:34(22):2654–8.

    Article  PubMed  Google Scholar 

  3. 3.

    Vaccaro V, Sperduti I, Vari S, et al. Metastatic pancreatic cancer: is there a light at the end of the tunnel? World J Gastroenterol. 2015;21(16):4788–801.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12(6):319–34.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27(4):358–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136–44.

    Article  PubMed  Google Scholar 

  8. 8.

    Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42(10):1533–9.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

  10. 10.

    Tzeng CWD, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16(5):430–8.

    Article  PubMed  Google Scholar 

  11. 11.

    Bickenbach KA, Gonen M, Tang LH, et al. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol. 2012;19(5):1663–9.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19(3):266–74.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4): e1000267.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Lim K-H, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17(2):192–200.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Schober M, Javed MA, Beyer G, et al. New advances in the treatment of metastatic pancreatic cancer. Digestion. 2015;92(3):175–84.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484–92.

    Article  PubMed  Google Scholar 

  17. 17.

    Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg. 2006;244:524–35.

    Article  Google Scholar 

  18. 18.

    Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14(1):118–27.

    Article  PubMed  Google Scholar 

  19. 19.

    De Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102(3):256–63.

    Article  PubMed  Google Scholar 

  20. 20.

    Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

Special thanks goes to Professor Paolo Pederzoli, ‘Maestro’ of surgery for all of us.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Isabella Frigerio.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Frigerio, I., Regi, P., Giardino, A. et al. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?. Ann Surg Oncol 24, 2397–2403 (2017). https://doi.org/10.1245/s10434-017-5885-4

Download citation

Keywords

  • Overall Survival
  • Liver Metastasis
  • Gemcitabine
  • Pancreatic Fistula
  • Pancreatic Resection